GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Monte Rosa Therapeutics Inc (NAS:GLUE) » Definitions » Equity-to-Asset

Monte Rosa Therapeutics (Monte Rosa Therapeutics) Equity-to-Asset : 0.57 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Monte Rosa Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Monte Rosa Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $152.52 Mil. Monte Rosa Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was $266.75 Mil. Therefore, Monte Rosa Therapeutics's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.57.

The historical rank and industry rank for Monte Rosa Therapeutics's Equity-to-Asset or its related term are showing as below:

GLUE' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.1   Med: 0.79   Max: 0.97
Current: 0.57

During the past 5 years, the highest Equity to Asset Ratio of Monte Rosa Therapeutics was 0.97. The lowest was -1.10. And the median was 0.79.

GLUE's Equity-to-Asset is ranked worse than
58.59% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs GLUE: 0.57

Monte Rosa Therapeutics Equity-to-Asset Historical Data

The historical data trend for Monte Rosa Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Monte Rosa Therapeutics Equity-to-Asset Chart

Monte Rosa Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
-1.10 -0.99 0.95 0.79 0.59

Monte Rosa Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.79 0.77 0.73 0.59 0.57

Competitive Comparison of Monte Rosa Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Monte Rosa Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Monte Rosa Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Monte Rosa Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Monte Rosa Therapeutics's Equity-to-Asset falls into.



Monte Rosa Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Monte Rosa Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=179.25/303.755
=

Monte Rosa Therapeutics's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=152.519/266.746
=0.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Monte Rosa Therapeutics  (NAS:GLUE) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Monte Rosa Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Monte Rosa Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Monte Rosa Therapeutics (Monte Rosa Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
645 Summer Street, Suite 102, Boston, MA, USA, 02210
Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body's natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enables to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates.
Executives
Edmund Dunn officer: Principal Accounting Officer MONTE ROSA THERAPEUTICS, INC., 321 HARRISON AVENUE, SUITE 900, BOSTON MA 02210
Anthony M. Manning director C/O PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Jan Skvarka director C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9
Philip Nickson officer: General Counsel MONTE ROSA THERAPEUTICS, INC., 40 GUEST STREET, BOSTON MA 02135
Julian G Jones officer: Chief Business Officer MONTE ROSA THERAPEUTICS, INC., 645 SUMMER STREET, SUITE 102, BOSTON MA 02210
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Joshua Makower 10 percent owner 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Paul Edward Walker 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Versant Venture Capital Vi, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Edward T Mathers 10 percent owner C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Kimberly Blackwell director C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Cormorant Private Healthcare Fund Ii, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
New Enterprise Associates 17, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 17, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093

Monte Rosa Therapeutics (Monte Rosa Therapeutics) Headlines